EP237: Brain Folate Connection: Cerebral Folate, FRAAs, and Leucovorin - Emily Gutierrez, DNP
In a Nutshell
Folate receptor alpha autoantibodies block folate transport into the brain, creating cerebral folate deficiency that drives autism, PANS/PANDAS, treatment-resistant depression, and schizophrenia in roughly 38-83% of affected populations. Folinic acid (leucovorin) bypasses blocked receptors via the reduced folate carrier backup system, with Italian research showing 10% autism rates when given to antibody-positive pregnant women versus 65% with standard folic acid. Treatment requires addressing inflammation first, optimizing B12, then titrating folinic acid at 2mg/kg twice daily while monitoring for glutamate excitotoxicity and monoamine increases.
These notes were generated by AI and may contain inaccuracies.
The Better Health Guide podcast explores complex chronic conditions and ways to build resilience, improve vitality, and achieve better health. Content is for informational purposes only and not intended to diagnose, treat, or cure any illness. All health-related decisions should be discussed with personal medical authority.
Episode 237 explores the brain folate connection, cerebral folate deficiency, folate receptor alpha autoantibodies, and leucovorin. Guest is Dr. Emily Gutierrez, doctorally prepared nurse practitioner and nationally recognized expert in functional medicine with advanced clinical training in both pediatric and adult care.
Dr. Emily Gutierrez brings a root cause evidence-based approach to optimizing neurological and mental health across the lifespan. She holds a doctor of nursing practice from Johns Hopkins University, specializes in translational medicine, and has served as adjunct faculty at Johns Hopkins University for six years teaching integrative and functional health. She is a fellow of the Medical Academy of Pediatric Special Needs, an Institute for Functional Medicine certified practitioner, a certified clinical nutritionist, and a primary care mental health specialist. Her clinical background includes extensive training in neuronutrition, genomics, and integrative strategies to support complex mental health and neurodevelopmental conditions. She serves as chief scientific medical liaison and formulator for Neuronutrition, developing clinically informed research-backed supplements that support brain function, mood balance, and overall neurological resilience.
Dr. Gutierrez became passionate about working with children with complex conditions like autism, PANS, and PANDAS due to her personal health journey. From teenager to young mom, she struggled with mental health and anxiety, and experienced a serious postpartum year that was radically transformative. She learned many things to help her mental health beyond medication. In 2015, she opened Neuronutrition Associates in Austin, Texas, one of the first pediatric-focused functional medicine clinics in Texas. Patients came with chronic illnesses that the allopathic paradigm had little to offer in terms of reversing what was happening, such as autism.
In autism, mainstream approaches offer behavioral therapies and antipsychotics, but do not focus on understanding the underlying reasons behind the disorder. When opening the practice, many chronically ill children came after parents had exhausted mainstream specialists with no improvement. Dr. Gutierrez notes that when you've helped one child with autism, you've helped one child with autism because they're so unique. However, seeing children start to have language, participate in school without special services, fuels the passion to help these children.
The discussion focuses on children significantly impacted by autism, not those who are generally functional, verbal, and able to manage their own lives. Dr. Gutierrez acknowledges that autism needs to be redefined with subtypes. Some people on the spectrum are high-functioning and intelligent in certain areas, while others experience severe and profound symptoms where normally developing children (approximately 80% of cases) experience a triggering event leading to loss of eye contact, loss of words, regression into their own world, and potential loss of skills like potty training. Symptoms can include head banging, sleep disturbances, and eating difficulties.
In 2004, an original research article was published in the New England Journal of Medicine that started breaking the science around folate in the brain. Serum folate in blood can appear normal while cerebral spinal fluid folate is deficient, which is cerebral folate deficiency. This deficiency affects brain development and functioning. Folate receptor alpha autoantibodies create roadblocks in folate transport from the body to the brain. An autoimmune inflammatory process occurs where the body makes a pathway for folate that is not as readily available into the brain. This is compared to Hashimoto's thyroiditis where free thyroid hormone exists but cannot enter cells.
Folic acid is the synthetic derivative, 20-fold cheaper than other forms, and requires reduction through NADPH and genomically encoded enzymes like dihydrofolate reductase to become active. Folinic acid (5-formyl tetrahydrofolic acid, also known as leucovorin) and methyl folate (5-methyl tetrahydrofolate) are active forms with specific roles in transport into the brain and other tissues. The American College of Obstetrics and Gynecology still recommends 4 milligrams of folic acid daily for pregnant women as of 2026.
A 2026 study by Italian researchers randomized pregnant women with folate antibodies into groups receiving either 15 milligrams of folinic acid daily or standard folic acid daily. In the folinic acid cohort, only 10% of children had an autism diagnosis, while in the folic acid group, approximately 65% of children were diagnosed with autism. This is preliminary research with a small sample size.
Folate is considered a life-giving nutrient with critical roles in DNA synthesis, cell division, myelination (requiring S-adenosylmethionine to myelinate basic protein and maturate oligodendrocytes), monoamine and neurotransmitter production, methionine to homocysteine regulation cycle, lipid metabolism, and amino acid metabolism. The brain requires approximately three times as much folate as peripheral tissues.
Symptoms of folate receptor autoantibodies vary by life stage: infancy may show small head circumference or acquired microcephaly; toddlers may experience hearing loss or seizures; small children may have tics, gait problems, or PANS/PANDAS presentations; adolescents may develop PANS/PANDAS, schizophrenia onset, or treatment-resistant depression; older adults may show neurodegenerative conditions like Parkinson's and dementia. Global symptoms include psychotic decline, developmental stagnation or regression, hypotonia, dystonia, spasticity, insomnia, OCD, and depression.
Cerebral folate deficiency can result from folate receptor autoantibodies, rare pathogenic gene variants, mitochondrial dysfunction (as folate transport requires significant energy), and dietary insufficiency. Mitochondrial dysfunction affects different mechanisms of folate transport through the brain. Dietary causes include children eating limited beige foods or PANS/PANDAS children who suddenly restrict to only eating meat.
Dr. Gutierrez's clinical approach involves discovering what the child has that they do not need that is stressing their immune system, and what they may be missing to achieve homeostasis. The focus is on identifying and removing stressors while replacing deficiencies to restore balance.
Meta-analysis by Rosnol and Fry published in 2021 in the Journal of Personalized Medicine found approximately 44% of those with cerebral folate deficiency also had autism, and among people with autism, about 38% had cerebral folate deficiency. Folate receptor antibody prevalence in these cohorts was 71%, with statistically significant p-values. Children with autism were approximately 19 times more likely to have folate receptor alpha antibodies than typically developing children or siblings. Worsening autism and irritability are observed when these antibodies are present.
Nancy O'Hara and Lindsay Wells discovered folate receptor antibodies in approximately 63.8% of their PANS/PANDAS cohort. In Dr. Gutierrez's clinical experience, the rate appears to be around 65% when discussing likelihood with parents of children with PANS/PANDAS.
Cerebral folate deficiency has been found in treatment-resistant depression (36%) and refractory schizophrenia (83.5%). Dr. Gutierrez tests for these antibodies regardless of diagnosis when neuroinflammatory stress is being addressed.
Autism and PANS/PANDAS frequently co-occur and are often missed. Dr. Gutierrez described an 18-year-old patient with profound autism (level two to three) who developed sudden catatonia. After travel to Mexico, the mother had a severe parasite infection. The patient was empirically treated for parasites and possible infection, resulting in complete resolution of catatonia after six weeks. This case demonstrates how catatonia could have been misattributed to worsening autism.
Dr. Gutierrez believes testing should extend beyond PANS, PANDAS, autism, depression, and schizophrenia. She has observed positive cerebral folate deficiency symptoms and folate receptor alpha antibodies in obsessive-compulsive disorder populations. A 2016 study by Wells and Henchi in Lyme disease patients (n=68) found 42 individuals with vector-borne illnesses, with approximately 62% having folate receptor alpha antibodies. Those with more severe forms (soluble or colloquially called floating antibodies) had Borrelia, but the most common vector-borne illness was Bartonella.
Folate receptor antibodies have implications for mothers preparing for pregnancy. The Italian study referenced women with positive antibodies who were treated with specific folate forms. Preconception screening is particularly important for mothers who already have a child with neurodevelopmental delay, as having one affected child increases likelihood of having a second affected child. This preparation should become routine and standard of care.
Folate transport into the brain occurs primarily through receptors on the choroid plexus, which is more scientifically accurate to reference than the blood-brain barrier for this mechanism. The folate receptor alpha on the choroid plexus is encoded by the FL1 gene, with both common variants and pathogenic variants affecting function. This receptor has the highest affinity for methylated folate and facilitates transport through receptor-mediated endocytosis followed by proton-coupled folate transport to release folate into the cerebrospinal fluid (CSF). This energy-dependent process requires ATP, making it less efficient in individuals with mitochondrial dysfunction or neuroinflammatory stress.
Folate receptor alpha antibodies can disrupt transport by binding to or blocking the receptor, sometimes causing the receptor to detach from the choroid plexus and become soluble. This disruption leads to reduced folate levels in the CSF. When the primary receptor is compromised, the reduced folate carrier (encoded by the solute carrier 19A1 gene) serves as a backup transport mechanism. This carrier functions as an ion exchanger, transporting folate into the brain while exporting organic ions like thiamine. The reduced folate carrier has high affinity for folinic acid and can transport it into the CSF when methylated folate transport is impaired.
The folate receptor alpha primarily transports the methyl form of folate, with approximately 1,000 times greater affinity for methyl folate compared to folinic acid. Folinic acid enters through the reduced folate carrier backup system and converts to the methylated form in the brain. The MTHFS genomic variant is a rare pathogenic variant (affecting approximately 12 people worldwide) that prevents conversion of folinic acid to methylated form and represents an FDA contraindication for folinic acid administration.
Folate receptor antibodies are present in multiple tissues including the placenta, intestinal epithelium, genital tract, lungs, kidney, thyroid, and retina. These tissues also express the reduced folate carrier as a backup transport mechanism. The research has not yet established whether antibodies affecting brain transport similarly impact other organs, though mechanistically this is plausible. Folate transport issues in the genital tract and placenta have implications for fertility and conception.
Autism is characterized as an immune-mediated neuropsychiatric condition arising from bodily stress, with oxidative stress, gut dysbiosis, environmental toxicants, co-infections, and untreated infections contributing to development. Approximately 10% of autism cases involve genomic variants, while 80% involve more common variants in pathways such as glutathione production and mannose-binding lectin pathogen clearance. The condition involves inability to tolerate redox imbalance and oxidative stress, preventing return to homeostasis. Family clustering research by Dr. Quadros in 2018 found that autism family members (siblings and parents) were 70% more likely to have folate receptor alpha antibodies compared to 29% in unaffected controls.
Italian research examined 210 pregnant mothers, finding 36 positive for folate receptor alpha antibodies. In randomized groups of 15 and 14 infants born to antibody-positive mothers, those receiving folinic acid showed lower autism incidence compared to those receiving folic acid. Children can be born with folate receptor alpha antibodies, and maternal antibody status during pregnancy may contribute to later autism or cerebral folate deficiency development. The presence of antibodies does not guarantee autism development but signals potential compromised folate transport into the brain.
The reduced folate carrier backup system efficacy depends on individual response, dosing, brain oxidation levels, and redox stress. Both the folate receptor alpha and reduced folate carrier require energy, though the receptor demands more. Nearly every child with autism shows some degree of mitochondrial deficiency, either true mitochondrial disease or acquired mitochondrial dysfunction. Common findings include acetylcarnitine deficiencies, with treatment involving carnitine supplementation, ubiquinol, coenzyme Q10, and B vitamins. Mitochondrial optimization requires addressing underlying stressors including infections, inflammatory conditions, allergies, dietary factors, environmental toxicants, heavy metals, and mycotoxins.
Mitochondrial rescue nutrients include carnitine for children, coenzyme Q10, and B vitamins. Additional tools like methylene blue have shown remarkable results in managing fatigue, headaches, muscle tension, and sleep requirements in certain patient populations, including those with Bartonella managed by specialists like Dr. Amy Offit. NAD IV therapy may be considered for older adolescents and adults.
Cerebral spinal fluid taps for folate assessment are rarely performed clinically, with access limited outside major research centers. Standard laboratory testing (Quest, LabCorp) measures folic acid without distinguishing between 5-formyl tetrahydrofolate (folinic acid) and 5-methyl tetrahydrofolate (methyl folate). High serum folic acid may indicate absorption issues, while low levels suggest significant problems. Testing is performed only once because folate supplementation elevates levels, potentially masking underlying issues. High serum folate may correlate with reduced natural killer cell cytotoxicity and increased cancer risk, particularly GI cancers.
Homocysteine serves as an ancillary marker for folate status, though levels may remain low in young children despite poor methylation and folate receptor antibodies. The highest homocysteine trends observed clinically reach 6-7. Mean corpuscular volume (MCV) and B12 levels require careful interpretation, as B12 can appear elevated in serum while being deficient at the cellular level due to transport and absorption issues. Folate trapping occurs when B12 is insufficient, making B12 optimization essential before initiating folinic acid therapy.
B12 optimization is critical before starting folinic acid, particularly in vegan families or children with limited diets consisting primarily of processed carbohydrates. Methylcobalamin, hydroxocobalamin, and adenosylcobalamin are preferred over cyanocobalamin. The functional medicine panel approach prioritizes FRAT testing over routine folic acid measurement due to the limited clinical value of standard folate testing in this context.
Serum B12 testing has limitations similar to folate testing. If levels are super low, they are super low, but high levels do not necessarily indicate adequate B12 status. B12 absorption, transport, and cellular uptake are heavily genomically influenced through intrinsic factor, transcobalamin genes, and mitochondrial uptake mechanisms. Diet also plays a significant role in B12 status.
Homocysteine is a valuable marker to assess because methionine needs to recycle homocysteine back into methionine during the methionine cycle, creating S-adenosylmethionine (SAMe) and providing methyl donors, a process requiring B12. If folinic acid is provided to the brain and cerebrospinal fluid but the tissue cannot remethylate it, folate becomes trapped in the cycle.
Clinical experience shows patients do better when B12 is supported before or alongside folinic acid treatment. In autism treatment at the Medical Academy of Pediatric Special Needs, B12 injections are frequently administered. A typical protocol for a six-year-old involves two milligrams of B12 every other day for six months, with parents administering injections at home when the child is asleep or after a bath. This brings B12 levels very high, which may exceed reference ranges, but B12 is water-soluble with no known toxicity signs. These heroic doses support methylation, allowing proper methylation when folate is added and improving overall biochemical homeostasis.
Different forms of B12 have varying tolerability. Hydroxycobalamin may be better tolerated by some individuals who find methylcobalamin too agitating or irritable. Cyanocobalamin, found in energy drinks, contains cyanide. Hydroxycobalamin can cleave cyanide from cyanocobalamin in cases of cyanide poisoning. Adenosylcobalamin has more literature supporting it as the mitochondrial form. For injections, methylated B12 is typically used. For compounded personalized nutrients, a combination of half adenosyl and half methyl may be used. Greater sensitivity to methyl B12 may indicate sensitivity to folinic acid as well.
The FRAT test from ReliGen (frat.com) is currently the only available test for folate receptor alpha antibodies, though a company in Austin, Texas is developing a similar test. Dr. Shri Ginan serves as medical director and is available for questions. The test must be ordered by a medical provider, costs approximately $300, and is not covered by insurance. It requires a blood draw, which can be challenging in pediatrics. Testing kits can be taken to local lab companies or Lab Test Now for collection.
Patients need to stop all folate supplementation for 48 hours before testing, though three days is recommended to ensure accurate results. Turnaround time has improved from 3-4 months to 4-5 weeks.
The FRAT test currently reports results as positive or negative with a numeric value but no established reference range. Clinically, higher numbers correlate with more severe presentations. There are different types of folate receptor alpha autoantibodies:
- Blocking antibodies: Prevent folate from entering the brain, similar to a key stuck in a lock
- Binding antibodies: Antibodies bound to the receptor causing dysfunction without completely blocking it
- Soluble (floating) antibodies: Floating antigen-antibody complex lacking membrane anchoring, representing the most severe form
The most severe presentations involve two positives, particularly combinations including the soluble form. Approximately 5% of tested children show soluble antibodies and tend to have greater diagnostic severity at presentation, including seizure disorder comorbidities and more severe autism presentations with neuropsychiatric symptoms.
Treatment approach varies based on antibody type and severity. For soluble antibodies, inflammation should be addressed for at least one month before introducing B12 or folinic acid. Neuroinflammatory calming interventions are used initially. Dosing of folinic acid depends on severity, with the standard starting dose being 2 milligrams per kilogram, maxing at 25 milligrams twice daily. However, some patients may require higher doses up to 75 milligrams twice daily based on clinical response, particularly for speech and ADHD symptoms.
The most clinically significant combination appears to be soluble folate receptor antibodies combined with positive binding. The soluble form is considered the most severe result.
The soluble or floating folate receptor represents inflammation causing the receptor to detach from its docking station. The FRAT assay detects these floating receptors in blood. Folate binds to these floating receptors but cannot be properly transported into the brain. This reduces folate transport efficiency at the choroid plexus level.
When soluble folate receptors are present, inflammation management is prioritized before folate or B12 supplementation. Treatment may include:
- Specialized pro-resolving mediators (SPMs) like Prodrome GLA at high doses for neuroinflammatory treatment
- High-dose omega-3 fatty acids
- Dietary modifications including gluten-free and dairy-free approaches
- Sugar reduction
- Environmental toxin reduction
Identifying underlying inflammatory triggers is essential, including gut infections like strep, co-infections like Lyme disease, or non-infectious toxicants like mycotoxins.
Folate receptor alpha autoantibody status is not fixed and can wax and wane based on autoimmune stress levels. The test manufacturers recommend rechecking every 6 months to 1 year. This variability is similar to how motor and vocal tics can wax and wane. Some families have received positive FRAT results but no treatment guidance from ordering physicians, highlighting the need for provider education on result interpretation and treatment.
The increase in autism over recent decades appears to represent a genuine increase rather than improved awareness and diagnostics alone. More profound autism, non-speaking presentations, and severe cases are being observed. This suggests that cerebral folate deficiency and folate receptor autoantibody prevalence may also be increasing due to similar environmental and health factors contributing to overall increased childhood chronic illness.
Genetic variants represent potential rather than deterministic outcomes. Epigenetic influences including stress, trauma, and toxicity significantly impact gene function. Both removing stressors and introducing nutrients that bypass or optimize genetic inefficiencies are valuable treatment approaches.
Rare pathogenic genes like FOLR1 biallelic loss-of-function variants are extremely uncommon, with only 35 cases reported worldwide. These variants are on-label for leucovorin treatment. More common FOLR1 variants exist alongside other relevant genes including SLC19A1 (reduced folate carrier) and MTHFD2 (mitochondrial folate uptake).
The IntellxxDNA panel includes a folate antibody profile testing FOLR1, SLC19A1, MTHFR 677T, and MTHFD2. Research by Dong and Associates (2018) showed that homozygous MTHFR 677T variants increase likelihood of folate receptor antibodies. FOLR1 is considered the "star gene" due to its direct relevance to folate receptor function.
The more common FOLR1 heterozygous variant occurs in 11.3% of the population, while homozygous variants occur in 0.4%. This variant confers an autism odds ratio of 6.45. In a study cohort of 79 individuals, 13% had heterozygous variants and 6% had homozygous variants, with 56.3% of these showing positive FRAT results.
Genes influence multiple aspects of folate metabolism: methylation of folic acid to tetrahydrofolate to 5-methylenetetrahydrofolate to methylfolate, folate receptor alpha encoding for endocytosis through the brain, and SLC19A1 encoding the back-door reduced folate carrier through ion exchange.
Foods fortified with folic acid should be avoided in this population, as higher folic acid levels correlate with reduced natural killer cell cytotoxicity. California now requires fortification of corn and masa tortillas with folic acid, though fortification is not performed with bioactive forms like folinic acid or methylfolate.
Animal dairy products should be avoided because cow, camel, sheep, goat, and human milk can carry folate receptor alpha, with highest levels found in bovine milk. The issue relates to milk protein rather than A1/A2 variations. Even though folate receptor alpha antibodies have been found in human breast milk, breastfeeding is not discouraged due to other benefits.
Dairy tolerance is dose-dependent and individual. Some patients tolerate small amounts of lactose in leucovorin or occasional cheese consumption. The autoimmune reaction to dairy, overall inflammatory load, and autoimmune response status should guide decisions. During acute rescue phases, inflammatory foods may need complete elimination, but some can be reintroduced as balance is achieved over time.
Organic full-fat dairy is recommended for children who can tolerate it without folate absorption problems. Eggs are valuable for growth, though some children cannot eat them. The global recommendation is that anyone with folate receptor alpha antibodies should go on a dairy-free diet at least initially. Camel's milk was previously promoted as closest to human milk for children with autism around 5-10 years ago, but now evidence shows it contains high levels of folate receptor alpha antibodies, making it problematic.
EGCG is worth considering as it can inhibit dihydrofolate reductase in vitro, though this is not a global recommendation.
Blood draws can be challenging in this population, and test results may take a month or longer. The question arises whether not intervening empirically carries potential risk and harm for the child. First do no harm remains the guiding principle. With a classic regressive child presenting with profound autism, not trying treatment may cause more harm than good.
A test is not required to treat with folinic acid. Having a test is certainly helpful, as is having the genotypes, but neither is imperative. With informed consent covering what is being done, why, benefits, and risks, most parents are eager to start treatment rather than spend $300 on testing. Even if testing is negative, treatment may still be attempted. Initiating treatment and gauging response is preferred over not treating due to insufficient evidence.
Inflammation and infection should be addressed first for better treatment response. The functional medicine matrix helps identify stress sources and what needs removal or reduction to prepare the body for methylation. Once folinic acid reaches the brain, it must still be methylated. Methylation depends on the methionine to homocysteine pathway via B12, and the folic acid to methylated form conversion involves B6 and riboflavin (B2).
Initial assessment should identify co-infections, ensure the gut microbiome is balanced, provide adequate antioxidants, and support inflammation management. B12 is given for at least one week before adding other co-actors, followed by slow titration of folinic acid.
Neuroinflammation is another consideration before starting leucovorin. SPMs or prodrome GLA may be used to address inflammation or neuroinflammation drivers.
Glutamate excitotoxicity is commonly seen in this population and impacts microglial activation. Glutamate excess causes agitation, irritability, anxiety, stimming, poor sleep, and hand flapping. In neuropsychiatric disease, glutamate plays a role in obsessive-compulsive disorder and seizures.
Glutamate toxicity is driven by infection. Inflammatory cytokines cross through and incite microglia, the brain's primary immune cells. Glutamatergic overexcitability reflects the brain attempting homeostasis, but excess glutamate and insufficient GABA result in irritability.
Glutamate modulators include magnesium threonate, pyridoxal-5-phosphate, and high doses of inositol. Amantadine can be very helpful, though memantine is less effective.
Adding folinic acid to existing irritability and glutamate excitotoxicity can worsen symptoms. Once folinic acid enters the brain, it increases all monoamines including glutamate, potentially causing increased irritability. Parents may conclude leucovorin is terrible and want to discontinue. However, this response can predict a good outcome—folate is entering the brain and increasing everything, including glutamate.
Dr. Raymakers, one of the original researchers, suggested starting an antipsychotic during leucovorin therapy if irritability occurs, but this approach is typically avoided. Instead, the focus is on clearing infection, lowering glutamate, focusing on inflammation, and slow titration.
Oxidative stress exploration is particularly important for those with soluble folate receptor issues. Cytokine 13 panels assess interleukin-6 and tumor necrosis factor alpha, though serum levels have limitations as they are not CSF measurements. High serum levels likely indicate high brain levels.
Lion's mane has evidence for decreasing tumor necrosis factor alpha. In rare cases, anti-steroid medications may be prescribed. NAC is a cornerstone for decreasing oxidative stress in the brain, with studies on OCD using upwards of 3600 milligrams daily. The challenge with children is getting the nutrient in if they cannot swallow pills due to the terrible taste.
Children do not typically experience placebo or nocebo effects.
The standard dosing is 2 milligrams per kilogram with a maximum of 25 milligrams twice daily. FRA test results are taken into consideration but do not dictate dosing—response determines titration speed and amount.
Prescription leucovorin comes in 5-milligram tablets. A typical titration starts with 2.5 milligrams in the morning for 2-3 days, then adds 2.5 milligrams in the afternoon for 3-4 days, continuing upward. Titration to 25 milligrams twice daily may take up to 3 months depending on the child's size.
If a child becomes too excitable, does not sleep, or stims more, the dose may be reduced and held for weeks before attempting further increases. Some children take a year to reach therapeutic dose and respond beautifully with speech improvements.
The biggest signal in neurodevelopmental disorders is speech improvement. Children with zero words might gain a few; those with a few words might begin speaking in phrases. Treatment typically lasts 2-3 years. If no response occurs after a year, discontinuation may be considered. Sometimes regression upon discontinuation reveals benefits that were not fully recognized.
Blocking antibody results may indicate higher likelihood of hyperexcitability and agitation initially, but this is transient. A little activation can be a good sign indicating folate is reaching the brain and increasing monoamines.
One child who never slept through the night began sleeping 12 hours within a month of starting folinic acid—the only change made.
Even with negative blocking and binding antibodies, treatment may be considered based on genomic variance correlation and informed consent. Parents are informed of risks and benefits before attempting treatment.
Leucovorin is a racemic mixture containing active levofolinic acid (L form) and inactive dextrofolinic acid (D form). Levofolinic acid is difficult to access and approximately 10 times more expensive than regular leucovorin. Studies are underway using levofolinic acid.
Leucovorin contains dyes, excipients, fillers, and lactose. Some families prefer compounded formulations to avoid these. PD Labs in Austin, Texas, sources leucovorin affordably for this population. Compounding may be done as powder or liquid, with careful attention to dosing accuracy.
Insurance may cover 5 milligrams twice daily but not higher doses like 25 milligrams twice daily, which could cost $1000 monthly. The decision between prescription and compounded forms depends on insurance coverage, family preference, and whether the child can swallow capsules.
Over-the-counter folinic acid products are limited to half the pharmaceutical dose (2.5 milligrams or less) to comply with FDA regulations. Leucovorin can oxidize with light exposure and becomes unstable at higher temperatures. Oral peak occurs 1-2 hours after dosing with a plasma half-life of 30-60 minutes, necessitating twice-daily dosing. Active methylfolate has a longer half-life of 3-6 hours.
If stimulation occurs, afternoon dosing after school is preferable to bedtime dosing. Folate is excreted through the kidneys.
Even small amounts of over-the-counter folinic acid can be beneficial when not treating cerebral folate deficiency specifically.
Benefits may not be immediate, and stopping too soon may miss significant improvements. The FRAT test may show waning severity over time as homeostasis and autoimmunity improve, though many families do not repeat testing if the child is doing better.
After successful treatment, doses may be titrated back, with maintenance doses of 2.5-5 milligrams daily continued long-term rather than abrupt discontinuation from 50 milligrams.
High-dose folinic acid works by flooding the serum, allowing transport into the brain via the reduced folate carrier, which does not require mitochondrial energy and functions as an antiporter and ion transporter. Autoimmunity toward the reduced folate carrier is not known to exist.
Folate is the lynchpin supporting methionine, transsulfuration, DNA, tetrahydrobiopterin, and monoamines. The treatment provides folate availability that is then methylated and used for these essential functions.
The treatment does not address autoantibody production, which relates to decreasing oxidative stress through other interventions.
Folinic acid is water-soluble with few significant issues when dosed appropriately. Starting too fast or too high can lead to symptom exacerbation. The connection to tetrahydrobiopterin (BH4) is relevant as many in this population are low in BH4.
Side effects during treatment can be encouraging signs that the therapy is beginning to work. Once patients work through initial side effects, they typically see more significant results in treating conditions such as OCD, autism, depression, and hyperexcitability. These symptoms occur because of increased monoamines. When problems arise with tetrahydrobiopterin, going upstream remains important, and folate is still needed to support that pathway.
The GCH1 variant can decrease tetrahydrobiopterin levels, as published with Dr. Sharon Houseman Cohen and colleagues. For these patients, compounded BH4 may be given. Vitamin C can increase BH4 levels. Lithium carbonate has been studied pharmaceutically, and lithium orotate with BH4 presents an interesting possibility. The upstream model prioritizes supporting folate first, since folate supports BH4 production. BH4 depends on methionine, methylation, and folate pathways. Without correcting folate first, BH4 cannot work effectively.
Agitation, aggression, or sleep issues may indicate the need to slow titration, reduce doses, and work up more slowly. A listener reported a child with binding antibodies who experienced lowered seizure threshold and increased seizures when leucovorin was introduced. Cerebral folate deficiency itself can be a root cause of seizures. In such cases, neuroinflammation levels, glutamate cytotoxicity, and B6 support in the brain require evaluation. A common gene variant around B6 carries a high odds ratio for seizures. If B6 is unsupported and folinic acid triggers a reaction, pausing folinic acid and addressing other nutrient co-factors becomes necessary.
Bartonella may contribute to seizures, warranting consideration of vector-borne infections. Questions arise about whether high-dose folinic acid treats autism symptoms or addresses root causes. Folate receptor alpha autoantibodies may represent a root cause, raising further questions about whether low folate or autoimmunity is primary. If autoimmunity drives the issue, the real root cause may be infection or toxin exposure. The goal encompasses both repleting cerebral folate and potentially resolving autoimmunity. The autoimmune aspect may not persist for a lifetime once triggered.
Early intervention produces better outcomes in pediatrics. Significant improvement in autism severity is possible at age 16, but more profound results typically occur with three-year-olds. Inflammatory immune-mediated neuroinflammatory stress can be reduced through understanding the complex interplay of genomics, environment, infections, and immune factors leading to autoimmunity and poor folate transport. Cerebral folate deficiency and autism show bidirectional relationships, making it difficult to determine which came first.
Autism represents a complex neurodevelopmental condition requiring examination of all functional medicine matrix nodes. The exposome, parenting, therapeutic behaviors, nutrition, and nutrient levels all matter. The FRAT test provides valuable information but is not the only relevant factor. Parents may feel overwhelmed by this complexity. RFK's statement about leucovorin as an autism treatment was both thrilling and disappointing because it should have emphasized that autism involves significant cerebral folate deficiency and that folinic acid can reverse this deficiency and improve symptoms. The political framing led to increased FRAT testing orders, though the attention proved beneficial overall.
Plasma exchange and IVIG data for autoantibody removal and folate transport improvement are not yet available, though such research would be valuable. Immune modulation in autism includes various tools. IVIG represents a significant intervention for PANS/PANDAS that can decrease symptoms and improve autism simultaneously. Other therapeutics include low-dose naltrexone, low-dose immunotherapy, sublingual immunotherapy for allergies, and some homeopathy approaches. The goal involves training the immune system toward tolerance, as overwhelming the system with too many stressors impairs function. Removing immune stressors, providing functional tools, and utilizing emerging peptides for immune modulation and autism can help patients climb out of difficult states and potentially progress without ongoing interventions.
Daily supplement intake, sleep protection, and early rising for study and alone time form core practices. Nature time, animal care, and forest walks provide essential grounding. Basic practices receive attention despite challenges like increased eating out. Engaging in enjoyable activities while eliminating draining commitments and unhealthy relationships supports overall wellbeing. Health represents a daily journey.
Keep BetterHealthGuy in your library
Save the videos and channels worth coming back to, and find them again in one place.
